An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
(RTTNews) - Protara Therapeutics Inc. (TARA) is scheduled to present new interim data from Cohort A of its ongoing Phase 2 trial assessing investigational cell-based therapy, TARA-002, in patients ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
BALTIMORE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- November is Bladder Health Month, and the Urology Care Foundation (UCF), the official foundation of the American Urological Association, is lifting the lid ...
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...
Getting your Trinity Audio player ready... By DEVI SHASTRI Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the ...
Robotic surgery for bladder cancer speeds recovery, reduces pain, and improves quality of life. It also significantly reduces risks such as blood clots and can preserve functions like sexual health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback